Puma Biotechnology (PBYI) News Today $3.25 -0.22 (-6.34%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period PUMA SE: This Is The Right Time To BuyMarch 21, 2025 | seekingalpha.comPuma Biotechnology Stock Rises 35% in 6 Months: Here's WhyMarch 20, 2025 | msn.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 32.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 487,368 sharesMarch 20, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200-Day Moving Average - Should You Sell?March 19, 2025 | americanbankingnews.comPuma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving Average - Here's What HappenedPuma Biotechnology (NASDAQ:PBYI) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?March 19, 2025 | marketbeat.comPuma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comPuma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by StockNews.comStockNews.com lowered shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Saturday.March 8, 2025 | marketbeat.comZooming In On Puma Biotechnology's EarningsMarch 7, 2025 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)March 5, 2025 | businesswire.comPuma Biotechnology to Present at Barclays Annual Global Healthcare ConferenceMarch 5, 2025 | businesswire.comResults: Puma Biotechnology, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMarch 2, 2025 | finance.yahoo.comPuma Biotechnology (NASDAQ:PBYI) Upgraded to "Strong-Buy" at StockNews.comStockNews.com raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Friday.March 1, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday.March 1, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Posts Earnings Results, Beats Expectations By $0.29 EPSPuma Biotechnology (NASDAQ:PBYI - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%.February 28, 2025 | marketbeat.comQ4 2024 Puma Biotechnology Inc Earnings Call TranscriptFebruary 28, 2025 | gurufocus.comPuma Biotech stock rises as Q4 earnings surpass expectationsFebruary 27, 2025 | investing.comPuma Biotechnology sees FY25 product revenue $192M-$198MFebruary 27, 2025 | markets.businessinsider.comPuma Biotechnology sees Q1 product revenue $41M-$43MFebruary 27, 2025 | markets.businessinsider.comPuma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comPuma Biotechnology Inc (PBYI) Q4 2024 Earnings: EPS of $0. ...February 27, 2025 | gurufocus.comPuma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | businesswire.comPuma Biotechnology to Present at TD Cowen’s 45th Annual Health Care ConferenceFebruary 26, 2025 | finance.yahoo.comPuma Biotechnology to Present at TD Cowen's 45th Annual Health Care ConferenceFebruary 26, 2025 | businesswire.comInvestors in Puma Biotechnology (NASDAQ:PBYI) have unfortunately lost 73% over the last five yearsFebruary 23, 2025 | finance.yahoo.comPuma Biotechnology (PBYI) Projected to Post Quarterly Earnings on ThursdayPuma Biotechnology (NASDAQ:PBYI) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=335006)February 21, 2025 | marketbeat.comPuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial ResultsFebruary 13, 2025 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 5, 2025 | businesswire.comMillennium Management LLC Reduces Stake in Puma Biotechnology IncFebruary 3, 2025 | gurufocus.comZacks Research Analysts Increase Earnings Estimates for PBYIPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities research analysts at Zacks Research lifted their FY2025 EPS estimates for Puma Biotechnology in a research note issued to investors on Wednesday, January 22nd. Zacks Research analyst R. Department now forecasts that the biopharmaceutJanuary 27, 2025 | marketbeat.comQ4 EPS Estimate for Puma Biotechnology Boosted by AnalystPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Investment analysts at Zacks Research lifted their Q4 2025 earnings per share estimates for Puma Biotechnology in a research report issued to clients and investors on Wednesday, January 22nd. Zacks Research analyst R. Department now forecastsJanuary 24, 2025 | marketbeat.comIs Now The Time To Put Puma Biotechnology (NASDAQ:PBYI) On Your Watchlist?January 17, 2025 | finance.yahoo.comZacks Research Issues Pessimistic Estimate for PBYI EarningsPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Research analysts at Zacks Research reduced their FY2024 earnings per share (EPS) estimates for shares of Puma Biotechnology in a report released on Thursday, January 9th. Zacks Research analyst R. Department now forecasts that the biopharmacJanuary 13, 2025 | marketbeat.comEquities Analysts Set Expectations for PBYI FY2025 EarningsPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Investment analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for shares of Puma Biotechnology in a research report issued to clients and investors on Thursday, January 9th. Zacks Research analyst R. DepartmentJanuary 10, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells 9,437 Shares of StockJanuary 4, 2025 | insidertrades.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Insider Jeffrey Jerome Ludwig Sells 9,437 SharesPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) insider Jeffrey Jerome Ludwig sold 9,437 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the transaction, the insider now owns 108,951 shares in the company, valued at approximately $343,195.65. The trade was a 7.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.January 3, 2025 | marketbeat.comAlan H. Auerbach Sells 33,841 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) CEO Alan H. Auerbach sold 33,841 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at $22,143,473.10. This represents a 0.48 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.January 3, 2025 | marketbeat.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | businesswire.comZacks Research Has Bullish Forecast for PBYI FY2025 EarningsPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Stock analysts at Zacks Research upped their FY2025 earnings per share estimates for shares of Puma Biotechnology in a report issued on Tuesday, December 24th. Zacks Research analyst R. Department now expects that the biopharmaceutical companDecember 27, 2024 | marketbeat.comWith 49% stake, Puma Biotechnology, Inc. (NASDAQ:PBYI) seems to have captured institutional investors' interestDecember 23, 2024 | uk.finance.yahoo.comHC Wainwright Reiterates Buy Rating for Puma Biotechnology (NASDAQ:PBYI)HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Puma Biotechnology in a research report on Monday.December 23, 2024 | marketbeat.comPuma Biotechnology: Continuing To Push Their Aurora Kinase Story ForwardDecember 16, 2024 | seekingalpha.comPuma Biotechnology (NASDAQ:PBYI) Lowered to "Buy" Rating by StockNews.comStockNews.com lowered Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research note on Friday.December 6, 2024 | marketbeat.com3 Emerging Biotech Stocks Developing Breakthrough TherapiesDecember 5, 2024 | stocknews.comPuma Biotechnology (NASDAQ:PBYI) Downgraded by StockNews.com to BuyStockNews.com cut Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research note on Friday.November 23, 2024 | marketbeat.comPuma Biotechnology initiates ALISertib in CAncer trialNovember 20, 2024 | markets.businessinsider.comBuy Rating Reiterated for Puma Biotechnology Amid Promising Phase 2 Trial and Strategic FDA EngagementNovember 20, 2024 | markets.businessinsider.comLos Angeles Capital Management LLC Acquires Shares of 245,695 Puma Biotechnology, Inc. (NASDAQ:PBYI)Los Angeles Capital Management LLC purchased a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 245,695 shares of the biopharmaceutical companyNovember 17, 2024 | marketbeat.comPuma Biotechnology Inc (PBYI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...November 8, 2024 | finance.yahoo.comPuma Biotechnology Reports Strong Q3 2024 GrowthNovember 8, 2024 | markets.businessinsider.comBarclays Reaffirms Their Sell Rating on Puma Biotechnology (PBYI)November 8, 2024 | markets.businessinsider.com Remove Ads Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Media Mentions By Week PBYI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PBYI News Sentiment▼1.060.62▲Average Medical News Sentiment PBYI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PBYI Articles This Week▼62▲PBYI Articles Average Week Remove Ads Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ArriVent BioPharma News Today Organogenesis News Today CureVac News Today GH Research News Today Nuvation Bio News Today CorMedix News Today Immunome News Today Arbutus Biopharma News Today Bicycle Therapeutics News Today Dianthus Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PBYI) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PBYI Stock Free PBYI Stock Alerts